MSOR3 Presentation Time: 5:10 PM

IF 16.4 1区 化学 Q1 CHEMISTRY, MULTIDISCIPLINARY Accounts of Chemical Research Pub Date : 2024-10-25 DOI:10.1016/j.brachy.2024.08.037
Zepaer Abudureheman MBBA , Tao Zhu MBBA , Dengyao Liu M.D., Ph.D.
{"title":"MSOR3 Presentation Time: 5:10 PM","authors":"Zepaer Abudureheman MBBA ,&nbsp;Tao Zhu MBBA ,&nbsp;Dengyao Liu M.D., Ph.D.","doi":"10.1016/j.brachy.2024.08.037","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>The study aimed to evaluate the combined efficacy of systemic therapy and iodine-125 seed implantation as a local treatment in patients with oligometastatic non-small cell lung cancer (NSCLC), defined by ≤3 metastatic organs and ≤5 metastatic lesions, and to identify factors that influence patient outcomes.</div></div><div><h3>Materials and Methods</h3><div>A retrospective review was conducted of 40 patients with oligometastatic NSCLC treated from January 2018 to June 2023 at our institution. Patients were divided into Group A (n=20), receiving both systemic therapy and iodine-125 seed implantation, and Group B (n=20), treated with systemic therapy alone. The primary outcome was progression-free survival (PFS), with overall survival (OS) serving as a secondary outcome. Survival analysis for PFS and OS was performed using Kaplan-Meier curves, with the Log-rank test for intergroup comparisons, and Cox regression analysis was used for univariate and multivariate analyses.</div></div><div><h3>Results</h3><div>The median PFS for Group A was 14.9 months (95% CI: 12.8-17.0), which was significantly longer than the 6.9 months (95% CI: 4.7-9.1) for Group B (HR=6.50, 95% CI: 4.60-9.20). The median OS was 28.7 months (95% CI: 19.5-37.9) for Group A, surpassing the 17.0 months (95% CI: 13.5-20.5) for Group B (HR=1.60, 95% CI: 1.05-2.40). Multivariate analysis highlighted intracranial metastasis as a significant risk factor for PFS. Influential factors for OS included oligometastatic status, the presence of brain metastases, histologic subtype, the use of immune checkpoint inhibitors (ICIs), driver mutations, anti-angiogenic treatments, and the implementation of iodine-125 seed implantation for local therapy.</div></div><div><h3>Conclusion</h3><div>In patients with oligometastatic NSCLC and stable primary lesions, the integration of systemic therapy with iodine-125 seed implantation markedly improves PFS and OS compared to systemic therapy alone. This underscores the value of iodine-125 seed implantation in the comprehensive treatment strategy, highlighting its significant role in enhancing patient survival outcomes.</div></div>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1538472124001739","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

The study aimed to evaluate the combined efficacy of systemic therapy and iodine-125 seed implantation as a local treatment in patients with oligometastatic non-small cell lung cancer (NSCLC), defined by ≤3 metastatic organs and ≤5 metastatic lesions, and to identify factors that influence patient outcomes.

Materials and Methods

A retrospective review was conducted of 40 patients with oligometastatic NSCLC treated from January 2018 to June 2023 at our institution. Patients were divided into Group A (n=20), receiving both systemic therapy and iodine-125 seed implantation, and Group B (n=20), treated with systemic therapy alone. The primary outcome was progression-free survival (PFS), with overall survival (OS) serving as a secondary outcome. Survival analysis for PFS and OS was performed using Kaplan-Meier curves, with the Log-rank test for intergroup comparisons, and Cox regression analysis was used for univariate and multivariate analyses.

Results

The median PFS for Group A was 14.9 months (95% CI: 12.8-17.0), which was significantly longer than the 6.9 months (95% CI: 4.7-9.1) for Group B (HR=6.50, 95% CI: 4.60-9.20). The median OS was 28.7 months (95% CI: 19.5-37.9) for Group A, surpassing the 17.0 months (95% CI: 13.5-20.5) for Group B (HR=1.60, 95% CI: 1.05-2.40). Multivariate analysis highlighted intracranial metastasis as a significant risk factor for PFS. Influential factors for OS included oligometastatic status, the presence of brain metastases, histologic subtype, the use of immune checkpoint inhibitors (ICIs), driver mutations, anti-angiogenic treatments, and the implementation of iodine-125 seed implantation for local therapy.

Conclusion

In patients with oligometastatic NSCLC and stable primary lesions, the integration of systemic therapy with iodine-125 seed implantation markedly improves PFS and OS compared to systemic therapy alone. This underscores the value of iodine-125 seed implantation in the comprehensive treatment strategy, highlighting its significant role in enhancing patient survival outcomes.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
MSOR3 演讲时间:下午 5:10
目的该研究旨在评估全身治疗和碘-125种子植入作为局部治疗手段对寡转移性非小细胞肺癌(NSCLC)患者的联合疗效,寡转移性非小细胞肺癌的定义是转移器官≤3个且转移病灶≤5个,并确定影响患者预后的因素。材料和方法对2018年1月至2023年6月在我院接受治疗的40例寡转移性NSCLC患者进行了回顾性研究。患者被分为A组(20人)和B组(20人),A组同时接受全身治疗和碘-125种子植入治疗,B组仅接受全身治疗。主要结果是无进展生存期(PFS),次要结果是总生存期(OS)。结果A组的中位无进展生存期为14.9个月(95% CI:12.8-17.0),明显长于B组的6.9个月(95% CI:4.7-9.1)(HR=6.50,95% CI:4.60-9.20)。A组的中位OS为28.7个月(95% CI:19.5-37.9),超过B组的17.0个月(95% CI:13.5-20.5)(HR=1.60,95% CI:1.05-2.40)。多变量分析强调颅内转移是影响PFS的重要风险因素。OS的影响因素包括寡转移状态、脑转移的存在、组织学亚型、免疫检查点抑制剂(ICIs)的使用、驱动基因突变、抗血管生成治疗以及局部治疗中碘-125种子植入的实施情况。这凸显了碘-125粒子植入在综合治疗策略中的价值,突出了其在提高患者生存率方面的重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Accounts of Chemical Research
Accounts of Chemical Research 化学-化学综合
CiteScore
31.40
自引率
1.10%
发文量
312
审稿时长
2 months
期刊介绍: Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
期刊最新文献
The change process questionnaire (CPQ): A psychometric validation. Differential Costs of Raising Grandchildren on Older Mother-Adult Child Relations in Black and White Families. Does Resilience Mediate the Relationship Between Negative Self-Image and Psychological Distress in Middle-Aged and Older Gay and Bisexual Men? Intergenerational Relations and Well-being Among Older Middle Eastern/Arab American Immigrants During the COVID-19 Pandemic. Caregiving Appraisals and Emotional Valence: Moderating Effects of Activity Participation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1